Non-opioid Niche Averitas Pharma offers FDA-approved, non-opioid topical therapy for neuropathic pain (postherpetic neuralgia and diabetic peripheral neuropathy of the feet), presenting a defensible position for expansion within non-opioid pain management channels and payer-approved alternatives.

Postmarket Partnerships Recent collaborations with clinical research organizations and patient advocacy groups (Celéri Health, American Chronic Pain Association) indicate openness to joint studies, clinician education, and patient programs that can be leveraged to drive adoption and real-world evidence for new or existing products.

US Footprint Acquisition by Grünenthal and active US presence through Averitas Pharma suggest strong market access foundations; leverage this footprint to expand physician outreach, KOL engagement, and payer negotiations within the U.S. neuropathic pain segment.

Clinical Evidence Focus Engagement in post-market observational studies and clinical research partnerships creates opportunities to sponsor or co-develop trials, generate value dossiers, and enhance market credibility with payers and providers.

Awareness Programs Past and ongoing patient-facing campaigns (Name That Pain, Speak For Your Feet) demonstrate effective patient education channels; scale these programs to boost brand recognition among HCPs and patients, supporting early diagnosis and treatment initiation.